China News Service, June 5th. Recently, many countries have welcomed China's Kexing vaccine through the World Health Organization's emergency use certification, saying that this move will help boost people's confidence.
Including the previously certified Sinopharm Covid-19 vaccine, two of the vaccines that have been included in the WHO's emergency use list have come from China.
Foreign media believe that this is expected to alleviate the current unfair global vaccine distribution, especially the plight of no vaccines available in low- and middle-income countries.
Data map: Singapore under the epidemic.
Bring new hope!
Kexing vaccine is welcomed by foreign people
After the news that Kexing vaccine was certified by the WHO was announced, on June 2, Singapore’s "Lianhe Zaobao" reported that Singapore medical practitioners would be able to introduce Kexing vaccines.
The Ministry of Health of Singapore said on the same day that the authorities are exploring the possibility of allowing private medical institutions to use the existing 200,000 doses of Coxing vaccine stocks, and will draw up details on prices, procedures for obtaining informed consent, and patient safety.
The local people in Singapore also welcomed this.
Singapore’s "Today" pointed out that some people have a history of allergies, which will restrict their vaccination of mRNA vaccines (referring to Pfizer and Modena vaccines), so many people hope to have alternative options.
Singapore infectious disease experts also said that the incidence of severe allergies from non-mRNA vaccines is low.
Darryl Cheong, a 24-year-old university student in Singapore, belongs to this group.
He said that he would consider vaccinating Kexing vaccine.
Yvonne Li, another 38-year-old public relations professional in Singapore, also praised the government’s decision on Coxing vaccine, “At least, I don’t have to wait too long to get the vaccine. This will help improve herd immunity. To push the country forward."
Philippine media on the 2nd quoted the Philippine Deputy Health Minister Maria Rosario Vergiere as saying that with the approval of the World Health Organization, the Coxing vaccine will be approved for use by more regulatory agencies around the world.
The report pointed out that in recent months, as more and more Filipinos receive vaccination, the use rate of Coxing vaccine has increased.
A recent public survey revealed that Kexing vaccine is one of the most popular vaccines in the country.
Data map: A bird's-eye view of the Brazilian town of Serana.
In the Brazilian town of Serana with a population of 46,000, 75% of adults have been vaccinated with two doses of Coxing vaccine, and the town has become a “healthy oasis” in Brazil.
The Associated Press described that nowadays, the new crown ward of the Serana Hospital has no burden, and the public can also enjoy the leisure of a picnic with the whole family on weekends.
Tourists from other cities and towns also choose to go to Serana for haircuts and outings to promote the recovery of the local economy.
Silva, an employee of a local snack shop, said, “A few weeks ago, people would not line up here or eat indoors. Now everything is starting to return to normal.” Mayor Capitri said that Serana plans to host 5,000 people. At large music festivals, all audiences are vaccinated against Kexing.
"Vaccinations have brought back our pride and hope for a new start next year."
In contrast, neighboring communities such as Ribeirão Preto, located only 12 miles west of Serana, have seen a surge in new crown cases as the variant strain spreads, and the occupancy rate of intensive care beds in the hospital has reached 95%.
On February 27, the first batch of semi-finished products of the new crown vaccine produced by Beijing Kexing Zhongwei Biotechnology Co., Ltd. arrived at Kuala Lumpur International Airport in Malaysia, and was officially delivered to Malaysia's Fama Company.
China News Agency issued a photo courtesy of the Chinese Embassy in Malaysia
Safe and effective!
Promote the vaccination process in multiple countries
Previously, independent experts from the WHO Strategic Advisory Expert Group (SAGE) evaluated the Phase III clinical trials of Kexing Vaccine in China, Brazil, Indonesia, Turkey and Chile, and said: “We are very confident that we will receive two doses. The Koxing vaccine is effective for adults (18-59 years old) to prevent new coronary pneumonia."
The Deputy Minister of Health of Chile, Daza, said that real-world test results have confirmed that the Coxing vaccine is effective in preventing symptomatic infections, reducing hospital admissions and preventing deaths caused by infections.
The emergency approval of the WHO for use has strengthened the world's confidence in Kexing vaccine.
According to a report from "Egypt Today", the Ministry of Health of Egypt stated on June 3 that according to clinical studies in many countries, the effective rate of China's Kexing vaccine for the general population was 91%.
Egyptian Health Minister Zayed said that Egypt will produce the first batch of Kohin vaccine by the end of June.
The results of a study released by the Ministry of Health of Indonesia on May 12 also showed that the new crown vaccine developed by China's Beijing Kexing Zhongwei Biotechnology Co., Ltd. has an effective rate of 94% for preventing symptomatic infections among medical staff.
On June 1, Beijing time, in Beijing Kexing Zhongwei Biotechnology Co., Ltd., located in Daxing District, Beijing, workers performed unpacking registration and scanning operations on the new crown inactivated vaccine packaging production line.
Photo by China News Agency reporter Hou Yu
The British Broadcasting Corporation (BBC) pointed out that Kexing vaccine has passed the World Health Organization's emergency use certification, which means that Kexing vaccine can enter the "New Coronary Pneumonia Vaccine Implementation Plan" (COVAX), which is expected to help solve the vaccine supply problem.
The Wall Street Journal and Reuters also believe that WHO's support will pave the way for the second Chinese vaccine to be used in poor countries, which will greatly promote the vaccination process.
WHO Director-General Tan Desai believes that Kexing vaccine is safe, effective and quality-assured. In particular, the vaccine is easy to store, making it particularly suitable for resource-poor environments. It is even more important for developing countries with barriers to transportation and storage. It is practical.
"It is vital now to get these'life-saving tools' into the hands of those who need them as soon as possible."
China's Kexing vaccine was approved, which "fully proves the safety and effectiveness of China's relevant vaccines and technical routes, and provides more powerful tools for the world to overcome the epidemic at an early date."
Chinese Foreign Ministry spokesperson Wang Wenbin pointed out that China will continue to support domestic vaccine companies to strengthen exchanges and cooperation with WHO and the "New Crown Vaccine Implementation Plan", and encourage more Chinese companies to conduct joint research and development and cooperative production of vaccines with foreign partners in order to achieve practical results. Action to support and help the vast number of developing countries to obtain vaccines to help the world overcome the epidemic at an early date.